NPS Pharmaceuticals, Inc.

Data analysis indicates parathyroid hormone improves bone microarchitecture

Published in Telemedicine Business Week, April 27th, 2005

NPS Pharmaceuticals, Inc. (NPSP) announced the results of two separate analyses of its Phase III TOP study data that corroborate previous findings that its product, PREOS (parathyroid hormone), improves bone microarchitecture and reduces the incidence of first and subsequent vertebral fractures in high-risk, postmenopausal, osteoporotic women.

The data, which include a bone biopsy study using microcomputed tomography (CT), a three-dimensional imaging technology, and a vertebral (spinal) fracture study in women at high risk for osteoporotic fracture, were presented at the National Osteoporosis Foundation (NOF) Sixth International Symposium on Osteoporosis in Washington,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Telemedicine Business Week

Source: Telemedicine Business Week (2005-04-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry